Potentiating Paclitaxel with its Homologous Nanovesicles: A Synergistic Strategy for Triple-Negative Breast Cancer Therapy
ACS Applied Materials & Interfaces · 2026
DOI: 10.1021/acsami.6c05220 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Applied Materials & Interfaces, 2026. Verfasst von Li Liu und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Basic Medical Science, Ningxia Medical University, Yinchuan, Ningxia CN 750004, China. Hauptthemen laut MEDLINE: Paclitaxel, Triple Negative Breast Neoplasms, Nanoparticles. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: Key Research and Development Program of Ningxia, Natural Science Foundation of Ningxia Province, National Natural Science Foundation of China (NSFC).
Abstract (Originalsprache)
Triple-negative breast cancer (TNBC) is highly invasive and has limited effective treatment options. Here, we developed natural extracellular nanovesicles derived from Taxus leaves (TLENs), which share the same plant origin as that of paclitaxel (PTX), to explore their potential as a targeted therapy carrier for TNBC. Through nontargeted metabolomics, it was found that it contains a large amount of flavonoids, with naringenin being the most abundant compound, as confirmed by LC-MS/MS analysis. Experiments have shown that the nanovesicles have significant anti-TNBC effects and, more importantly, can improve sensitivity to paclitaxel. At the cellular level, TLENs are internalized by TNBC cells via macropinocytosis, triggering an intracellular surge of reactive oxygen species that activates the JNK/p38 MAPK signaling cascade, thereby driving apoptosis while inhibiting cell proliferation, epithelial-mesenchymal transition, and migration. Beyond direct cytotoxicity, the oral coadministration of TLENs and PTX fundamentally remodeled the tumor microenvironment. The treatment effectively reversed immunosuppression by promoting dendritic cell maturation and enhancing cytotoxic CD8+ T cell infiltration while concurrently depleting regulatory T cells (Tregs) and myeloid-derived suppressor cells. This work innovatively proposes a "homologous combination" strategy that combines TLENs derived from the same plant with PTX. This combination exhibits enhanced anti-TNBC effects that are greater than those of either agent alone, providing a novel combination therapy for the treatment of TNBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Basic Medical Science, Ningxia Medical University, Yinchuan, Ningxia CN 750004, China.
- Cancer Institute, Institute of Medical Sciences, General Hospital of Ningxia Medical University, Yinchuan, Ningxia CN 750000, China.
- School of Inspection, Ningxia Medical University, Yinchuan, Ningxia CN 750004, China.
- Ningxia Key Laboratory of Infection and Immunity, Ningxia Medical University, Yinchuan, Ningxia CN 750004, China.
ORCID-Profile: Li Liu
Förderung
- Key Research and Development Program of Ningxia
- Natural Science Foundation of Ningxia Province
- National Natural Science Foundation of China (NSFC)
Zitieren
APA
Liu, L., Yan, Y., Zhang, J., Guan, Z., Liu, M., Wang, X., Duan, X., & Su, C. (2026). Potentiating Paclitaxel with its Homologous Nanovesicles: A Synergistic Strategy for Triple-Negative Breast Cancer Therapy. ACS Applied Materials & Interfaces. https://doi.org/10.1021/acsami.6c05220
Vancouver
Liu L, Yan Y, Zhang J, Guan Z, Liu M, Wang X, et al. Potentiating Paclitaxel with its Homologous Nanovesicles: A Synergistic Strategy for Triple-Negative Breast Cancer Therapy. ACS Applied Materials & Interfaces. 2026. doi:10.1021/acsami.6c05220
BibTeX
@article{Liu2026,
author = {Liu, Li and Yan, Yajuan and Zhang, Jiao and Guan, Zhirong and Liu, Miao and Wang, Xiaohua and Duan, Xiangguo and Su, Chunxia},
title = {Potentiating Paclitaxel with its Homologous Nanovesicles: A Synergistic Strategy for Triple-Negative Breast Cancer Therapy},
journal = {ACS Applied Materials & Interfaces},
year = {2026},
doi = {10.1021/acsami.6c05220}
}
EUVIMED